A spinout company developing technology based on innovative University of Queensland research has announced two partnerships that could revolutionise the manufacture and delivery of vaccines.
Vaxxas, founded by UQ’s technology transfer company UniQuest in 2011, will partner with global biotechnology company Merck (MSD) and German pharmaceutical manufacturer Harro Höfliger in two separate deals relating to the company’s needle-free vaccine delivery technology.
Vaxxas will receive A$18 million (US$12 million) in a combination of equity funding and option fees and is eligible to receive future option, development, and commercial milestone payments.